OBJECTIVE
• To explore the effects of brexpiprazole (Rexulti) as an adjunctive treatment to antidepressant monotherapy on sleep-wake patterns in depressed patients with sleep disturbances.
METHODS
• Design: Open-label, flexible-dose, noncontrolled experimental study; Duration: 14 weeks • Inclusion criteria: 18-65 years of age, diagnosis of MDD according to DSM-IV, current major depressive episode of greater than 10 weeks, inadequate response to at least 1 antidepressant treatment during the episode, currently taking an SSRI or SNRI at a stable dosage, currently experiencing sleep disturbances, have a mean latency to persistent sleep of ≥ 20 minutes during 2 consecutive nights of polysomnography (PSG) monitoring, have a latency to persistent sleep of no less than 15 minutes on either night, as well as an average sleep efficiency of < 85% on both nights. More extensive criteria in supplemental index.
• Exclusion criteria: Patients with a current psychiatric disorder or Axis I disorder other than MDD, Axis II disorder, history of hallucinations, delusions, or psychotic symptoms, patients at a significant risk of suicide, pregnancy, patients taking interacting medications (per the investigators), patients diagnosed with insomnia prior to the current major depressive episode (MDE), cognitive dysfunction, substance use disorder within previous 6 months, failed urine drug screen, history of neuroleptic malignant syndrome (NMS), patients meeting diagnostic criteria for any sleep disorder other than insomnia, abnormal EKG. More extensive criteria in supplemental material.
• Primary outcomes measured: change in sleep quality, sleep architecture, insomnia, and daytime alertness and functioning • Secondary outcome measures: incidence of treatment-emergent adverse effects, change in laboratory values or vital signs, change in EKG parameters, and risk of suicide • 44 patients were enrolled to receive brexpipraxole titrated to a dose of 3 mg per day (2 mg if tolerability became an issue) • No power due to being an exploratory noncontrolled study • Intent-to-treat data handling method
RESULTS
• 41 patients completed the study with 3 lost to follow-up 
CONCLUSION
• The limitations of the study and lack of strong evidence of clinically significant improvements reduce the clinical usefulness of brexpiprazole in the studied population.
• Given the current research and evidence supporting augmenting antidepressants with other SGA's, it's unlikely that brexpiprazole would be a preferred agent at this time.
• Future research would be beneficial with a larger sample size, longer duration, and placebocontrolled trial to determine the clinical usefulness of brexpiprazole.
